ABT:NYE-Abbott Laboratories (USD)

COMMON STOCK | Medical Devices | NYE

Last Closing Price

USD 126.79

Change

0.00 (0.00)%

Market Cap

USD 224.78B

Volume

0.01B

Avg Analyst Target

USD 129.53 (+2.16%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. It has collaboration agreement with Cereno Scientific AB (publ). The company was founded in 1888 and is based in North Chicago, Illinois. Address: 100 Abbott Park Road, North Chicago, IL, United States, 60064-6400

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-19 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MDT Medtronic plc

N/A

USD174.55B 45.37 24.54
SYK Stryker Corporation

N/A

USD102.96B 50.03 29.51
EW Edwards Lifesciences Corporati..

N/A

USD74.44B 51.83 57.11
BSX Boston Scientific Corporation

N/A

USD63.18B 120.24 34.88
ZBH Zimmer Biomet Holdings Inc

N/A

USD30.64B 33.42 17.67
BIO-B Bio-Rad Laboratories Inc

N/A

USD23.47B 5.88 4.20
BIO Bio-Rad Laboratories Inc

N/A

USD23.47B 5.88 4.20
STE STERIS plc

N/A

USD21.46B 65.62 36.23
SNN Smith & Nephew plc

N/A

USD16.19B 29.23 15.77
PEN Penumbra Inc

N/A

USD10.42B 662.16 656.61

ETFs Containing ABT

Symbol Name Weight Mer Price(Change) Market Cap
CURE Direxion Shares ETF Trust.. 0.00 % 1.01 %

N/A

USD0.17B
QDVG:F iShares V Public Limited .. 0.00 % 0.15 %

N/A

USD1.93B
ISDW:LSE iShares II Public Limited.. 0.00 % 0.60 %

N/A

USD0.33B
ISUS:LSE iShares II Public Limited.. 0.00 % 0.50 %

N/A

USD0.16B
ISWD:LSE iShares II Public Limited.. 0.00 % 0.60 %

N/A

USD0.33B
IUHC:LSE iShares S&P 500 Health Ca.. 0.00 % 0.15 %

N/A

USD1.93B
OPEN:LSE iShares Thomson Reuters I.. 0.00 % 0.25 %

N/A

USD0.04B
SXLV:LSE SSgA SPDR ETFs Europe II .. 0.00 % 0.15 %

N/A

USD0.29B
WHEA:LSE SPDR MSCI World Health Ca.. 0.00 % 0.30 %

N/A

USD0.45B
XDWH:LSE Xtrackers (IE) Public Lim.. 0.00 % 0.25 %

N/A

USD2.26B
XSHC:LSE Xtrackers (IE) Public Lim.. 0.00 % 0.12 %

N/A

USD0.62B
XUHC:LSE Xtrackers (IE) Public Lim.. 0.00 % 0.12 %

N/A

USD0.62B
OPEN:F iShares VI Public Limited.. 0.00 % 0.25 %

N/A

USD5.05M
XDWH:F Xtrackers (IE) Public Lim.. 0.00 % 0.25 %

N/A

USD1.10B
IHCU:LSE iShares V Public Limited .. 0.00 % 0.15 %

N/A

USD1.69B
ZPDH:F SSgA SPDR ETFs Europe II .. 0.00 % 0.15 %

N/A

USD0.29B
QDVG:XETRA iShares V Public Limited .. 0.00 % 0.15 %

N/A

USD1.95B
XDWH:XETRA Xtrackers (IE) Public Lim.. 0.00 % 0.25 %

N/A

USD2.26B
XUHC:XETRA Xtrackers (IE) Public Lim.. 0.00 % 0.12 %

N/A

USD0.62B
ZPDH:XETRA SSgA SPDR ETFs Europe II .. 0.00 % 0.15 %

N/A

USD0.29B
HIG-U:CA Brompton Global Healthcar.. 0.00 % 0.75 %

N/A

USD0.05B
LONG:CA CI Global Longevity Econo.. 0.00 % 0.96 %

N/A

USD0.07B
JSTC Tidal ETF Trust - Adasina.. 0.00 % 0.89 %

N/A

N/A
CBUF:XETRA iShares V Public Limited .. 0.00 % 0.25 %

N/A

USD0.37B
HHL-B:CA Harvest Healthcare Leader.. 0.00 % 0.99 %

N/A

N/A
FUD-A:CA First Trust Value Line Di.. 0.00 % 0.04 %

N/A

N/A
ISDU:LSE iShares II Public Limited.. 0.00 % 0.50 %

N/A

USD0.17B
HLAL Wahed FTSE USA Shariah ET.. 0.00 % 0.50 %

N/A

USD0.12B
CWS AdvisorShares Focused Equ.. 0.00 % 0.77 %

N/A

USD0.03B
SPMO Invesco S&P 500 Momentum .. 0.00 % 0.13 %

N/A

USD0.09B
FHLC Fidelity MSCI Health Care.. 0.00 % 0.08 %

N/A

USD2.70B
FUD:CA First Trust Value Line Di.. 0.00 % 0.04 %

N/A

USD0.01B
IHI iShares U.S. Medical Devi.. 0.00 % 0.42 %

N/A

USD8.16B
IXJ iShares Global Healthcare.. 0.00 % 0.46 %

N/A

USD3.25B
IYH iShares U.S. Healthcare E.. 0.00 % 0.43 %

N/A

USD2.66B
JHMH John Hancock Multifactor .. 0.00 % 0.40 %

N/A

USD0.05B
PJP Invesco Dynamic Pharmaceu.. 0.00 % 0.56 %

N/A

USD0.37B
PWB Invesco Dynamic Large Cap.. 0.00 % 0.56 %

N/A

USD0.78B
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

N/A

USD1.19M
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

N/A

USD1.19M
RXL ProShares Ultra Health Ca.. 0.00 % 0.95 %

N/A

USD0.22B
VHT Vanguard Health Care Inde.. 0.00 % 0.10 %

N/A

USD17.94B
FHI-B:CA CI Health Care Giants Cov.. 0.00 % 0.74 %

N/A

N/A
WBIG WBI BullBear Yield 3000 E.. 0.00 % 1.14 %

N/A

USD0.05B
XHC:CA iShares Global Healthcare.. 0.00 % 0.65 %

N/A

USD0.52B
XLV Health Care Select Sector.. 0.00 % 0.12 %

N/A

USD27.88B
HHL:CA Harvest Healthcare Leader.. 0.00 % 0.99 %

N/A

USD0.33B
MIVG:CA Mackenzie Ivy Global Equi.. 0.00 % 0.84 %

N/A

USD0.03B
LIFE:CA Evolve Global Healthcare .. 0.00 % 0.45 %

N/A

USD0.01B
ACT Enact Holdings Inc. Commo.. 0.00 % 0.99 %

N/A

USD3.26B
FHI:CA CI Health Care Giants Cov.. 0.00 % 0.72 %

N/A

USD0.06B
RWDC Direxion MSCI Defensives .. 0.00 % 0.46 %

N/A

USD7.11M
GDNA Goldman Sachs Human Evolu.. 0.00 % 0.50 %

N/A

USD0.06B
HHL-U:CA Harvest Healthcare Leader.. 0.00 % 0.99 %

N/A

N/A
MBOX Freedom Day Dividend ETF 0.00 % 0.39 %

N/A

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 15.80% 58% F 63% D
Dividend Return 1.23% 100% A+ 36% F
Total Return 17.03% 63% D 62% D-
Trailing 12 Months  
Capital Gain 18.65% 38% F 42% F
Dividend Return 1.60% 71% C- 27% F
Total Return 20.25% 38% F 40% F
Trailing 5 Years  
Capital Gain 204.93% 59% F 92% A-
Dividend Return 15.66% 100% A+ 56% F
Total Return 220.59% 65% D 92% A-
Average Annual (5 Year Horizon)  
Capital Gain 27.85% 50% F 87% B+
Dividend Return 1.97% 88% B+ 46% F
Total Return 29.82% 71% C- 88% B+
Risk Return Profile  
Volatility (Standard Deviation) 11.45% 96% A 80% B-
Risk Adjusted Return 260.36% 96% A 100% A+
Market Capitalization 224.78B 100% A+ 99% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 35.72 72% C- 19% F
Price/Book Ratio 6.65 27% F 15% F
Price / Cash Flow Ratio 28.45 46% F 14% F
EV/EBITDA 20.88 67% D+ 26% F
Management Effectiveness  
Return on Equity 19.66% 88% B+ 77% C+
Return on Invested Capital 9.61% 93% A 75% C
Return on Assets 7.19% 93% A 86% B
Debt to Equity Ratio 56.14% 45% F 59% F
Technical Ratios  
Short Ratio 2.54 73% C 50% F
Short Percent 0.58% 96% A 84% B
Beta 0.65 85% B 77% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector